Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and FeNO.

Brigham and Women's Hospital, Harvard Medical School, Asthma Research Center, Boston, Massachusetts, United States, "Sapienza" University of Rome, Public Health and Infectious Diseases, Rome, Italy
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 11.04). 11/2013; DOI: 10.1164/rccm.201307-1323OC
Source: PubMed

ABSTRACT Rationale: Beta-2 agonists are the treatment of choice for exercise-induced bronchoconstriction (EIB) and act through specific receptors (ADRB2). Arg16Gly polymorphisms have been shown to affect responses to regular use of beta-2 agonists. Objective: To evaluate the influence of the Arg16Gly receptor polymorphism on salmeterol bronchoprotection in EIB and assess predictors of bronchoprotection. Methods: A prospective, genotype-blinded, randomized trial was performed in 26 subjects (12 Arg16Arg and 14 Gly16Gly) with EIB, who were not on controller therapy. Subjects were administered salmeterol 50 mcg b.i.d. for two weeks and underwent an exercise challenge 9 hours after the first and last drug dose. In addition to genotype, FEV1, response to salmeterol, degree of EIB, and FeNO at baseline were examined for their association with loss of bronchoprotection (LOB). Measurements and Main Results: The maximum exercise-induced FEV1 fall was 27.9±1.4% during the run-in period, 8.1±1.2% (70.3±4.1% bronchoprotection) after the first salmeterol dose and 22.8±3.2% (18.9±11.5% bronchoprotection) after two weeks of salmeterol (p=0.0001). The Arg16Gly polymorphisms were not associated with the LOB in response to salmeterol. FeNO values at baseline were significantly related to the LOB (r=0.47, p=0.01). Mean change was a 74±13% LOB in subjects with FeNO levels >50ppb and a 7±16% gain in bronchoprotection in those with FeNO levels <25ppb (p=0.01). Conclusions: The LOB that occurs with chronic LABA use is not affected by ADRB2 Arg16Gly polymorphisms. High FeNO was associated with marked LOB. Use of long-acting beta-2 agonists prior to achieving a reduction in FeNO may need to be avoided. Clinical trial registration information available at (NCT00595361).

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Short- and long-acting β agonists (SABA and LABA) are bronchodilators for treating asthma. Bronchodilator response (BDR) is quantified by measuring air expired in the first second during a forced expiratory maneuver, prior to and following inhalation of SABA. BDR has been associated with a significant degree of heterogeneity, in part attributable to genetic variation. Heritability, the proportion of phenotypic variability accounted for by genetic variation is estimated to account for 50% of pulmonary function and 28.5% for BDR.Areas covered: A MEDLINE search for English articles published from January 1990 to June 2014 was completed using the terms: bronchodilator, bronchodilator response, short-acting bronchodilator, long-acting bronchodilator, β2 adrenergic receptor gene (ADRB2), asthma and pharmacogenomics. The effects of ADRB2 variants on BDR and the safety of SABA and LABA + inhaled corticosteroids have been studied with equivocal results. Single and candidate gene studies have identified variants in other genes that alter response to bronchodilators. Associations were recently observed between hospital admission rates and two rare ADRB2 polymorphisms: Thr164Ile and a 25 base pair insertion-deletion at nucleotide -376. This was the first report of life-threatening events associated with LABA being linked to rare ADRB2 variants.Expert opinion: Pharmacogenomic studies over the last two decades clearly demonstrate that polymorphisms alter patient response to bronchodilators in patients with asthma.
    Expert Opinion on Drug Metabolism &amp Toxicology 08/2014; DOI:10.1517/17425255.2014.939956 · 2.94 Impact Factor
  • American Journal of Respiratory and Critical Care Medicine 06/2014; 189(12):1487-93. DOI:10.1164/rccm.201403-0498UP · 11.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The goal of this review was to evaluate the association of β2-adrenergic receptor (ADRB2) gene polymorphisms with asthma and obesity. Asthma is the most common pediatric inflammatory disorder. The prevalence, severity, and hospitalization index for asthma have increased markedly in the last several decades. Interestingly, asthma is often diagnosed along with obesity. Genetic factors are essential for both conditions, and some of the candidate pleiotropic genes thought to be involved in the development of these diseases are ADRB2, vitamin D receptor (VDR), leptin (LEP), protein kinase C alpha (PRKCA), and tumor necrosis factor alpha (TNFα). The ADRB2 has been studied in multiple populations and more than 80 polymorphisms, mainly single-nucleotide polymorphisms, have been identified. For nonsynonymous Arg16Gly, Gln27Glu, and Thr164Ile, functional effects have been shown. In vivo, these polymorphisms have been evaluated to determine their association with both obesity and asthma, but the results are inconsistent and depend on the population studied or how the disease was defined. Currently, there are only few reports describing the genetic background for the comorbidity of asthma and obesity.
    Pediatric Allergy, Immunology, and Pulmonology 09/2014; 27(3):104-110. DOI:10.1089/ped.2014.0360 · 0.56 Impact Factor


Available from
Nov 17, 2014